Monte Rosa Therapeutics (GLUE) Operating Leases (2022 - 2026)

Monte Rosa Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $34.6 million for Q1 2026.

• In Q1 2026, Operating Leases fell 8.99% year-over-year to $34.6 million; the TTM figure through Mar 2026 stood at $34.6 million (down 8.99% YoY), while the FY2025 annual figure was $34.8 million, down 10.79% from the prior year.
• Operating Leases for Q1 2026 stood at $34.6 million, down from $34.8 million in the prior quarter.
• The five-year high for Operating Leases was $46.1 million in Q2 2022, with the low at $5.5 million in Q1 2022.
• The 5-year median for Operating Leases is $40.9 million (2024), against an average of $38.5 million.
• The sharpest annual moves came in 2023 and 2025: Operating Leases jumped 693.02% in 2023, then dropped 10.79% in 2025.
• Monte Rosa Therapeutics' Operating Leases stood at $43.9 million in 2022, then decreased by 2.27% to $42.9 million in 2023, then dropped by 9.04% to $39.0 million in 2024, then decreased by 10.79% to $34.8 million in 2025, then retreated by 0.61% to $34.6 million in 2026.
• Business Quant data shows GLUE's Operating Leases at $34.6 million in Q1 2026, $34.8 million in Q4 2025, and $35.9 million in Q3 2025.